Bio

Bio


Dr. Eggert is a board-certified, fellowship-trained pulmonologist and a clinical assistant professor in the Division of Pulmonary, Allergy, and Critical Care Medicine at Stanford University School of Medicine.

She is an expert in the diagnosis and management of diseases of the airway, with a focus on patients with allergic asthma. She also treats chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and chronic cough.

For every patient, Dr. Eggert develops a comprehensive care plan personalized to the individual’s unique needs and lifestyle. Her goals are always to deliver innovative, compassionate care of the highest quality to help each patient achieve the best possible outcome and quality of life.

Dr. Eggert has extensive research experience. During her fellowship, she worked closely with the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, where she designed projects to study the use of biologic medications to treat severe asthma, ABPA, and related conditions.

Dr. Eggert has authored review articles on asthma in adults for BMJ Best Practice. She has developed abstracts related to the prediction of asthma outcomes and switching and combining biologic therapies for asthma. She has presented her work at the American Thoracic Society and the American Academy of Allergy and Immunology annual meetings.

She is currently involved in several COVID-19 related research projects, including a study of the impact of COVID-19 on outcomes for asthmatic patients and another on the use of pulse oximeters to predict clinical decline after COVID-19 diagnosis.

Dr. Eggert also practices critical care at Stanford Health Care - ValleyCare and is actively engaged in teaching residents and fellows. She precepts both the Stanford Pulmonary Consult Service and the fellow’s clinics.

Clinical Focus


  • Pulmonary Disease

Academic Appointments


Honors & Awards


  • Alpha Omega Alpha, AOA Honor Society (6/2013)

Professional Education


  • Board Certification: American Board of Internal Medicine, Critical Care Medicine (2020)
  • Fellowship: Stanford University Pulmonary and Critical Care Fellowship (2020) CA
  • Board Certification: American Board of Internal Medicine, Pulmonary Disease (2019)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2016)
  • Residency: Icahn School of Medicine at Mount Sinai Hospital Internal Medicine Residency (2016) NY
  • Medical Education: Albert Einstein College of Medicine Montefiore Medical Center (2013) NY

Publications

All Publications


  • Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19. Allergy Eggert, L. E., He, Z., Collins, W., Lee, A. S., Dhondalay, G., Jiang, S. Y., Fitzpatrick, J., Snow, T. T., Pinsky, B. A., Artandi, M., Barman, L., Puri, R., Wittman, R., Ahuja, N., Blomkalns, A., O'Hara, R., Cao, S., Desai, M., Sindher, S. B., Nadeau, K., Chinthrajah, R. S. 2021

    Abstract

    BACKGROUND: It is unclear if asthma and its allergic phenotype are risk factors for hospitalization or severe disease from SARS-CoV-2.METHODS: All patients over 28 days oldtesting positive for SARS-CoV-2 between March 1 and September 30, 2020, were retrospectively identified and characterized through electronic analysis at Stanford. A sub-cohort was followed prospectively to evaluate long-term COVID-19 symptoms.RESULTS: 168,190 patients underwent SARS-CoV-2 testing, and 6,976 (4.15%) tested positive. In a multivariate analysis, asthma was not an independent risk factor for hospitalization (OR 1.12 [95% CI 0.86, 1.45], p=0.40). Among SARS-CoV-2 positive asthmatics, allergic asthma lowered the risk of hospitalization and had a protective effect compared to non-allergic asthma (OR 0.52 (0.28, 0.91), p=0.026); there was no association between baseline medication use as characterized by GINA and hospitalization risk. Patients with severe COVID-19 disease had lower eosinophil levels during hospitalization compared to patients with mild or asymptomatic disease, independent of asthma status (p=0.0014). In a patient sub-cohort followed longitudinally, asthmatics and non-asthmatics had similar time to resolution of COVID-19 symptoms, particularly lower respiratory symptoms.CONCLUSIONS: Asthma is not a risk factor for more severe COVID-19 disease. Allergic asthmatics were half as likely to be hospitalized with COVID-19 compared to non-allergic asthmatics. Lower levels of eosinophil counts (allergic biomarkers) were associated with a more severe COVID-19 disease trajectory. Recovery was similar among asthmatics and non-asthmatics with over 50% of patients reporting ongoing lower respiratory symptoms three months post-infection.

    View details for DOI 10.1111/all.14972

    View details for PubMedID 34080210

  • Asthma as a predictor of more severe outcomes in COVID-19 infection Eggert, L., Cao, S., He, Z., Dhondalay, G., Jiang, S., Collins, W., Sindher, S., Nadeau, K., Sharon Chinthrajah, R. MOSBY-ELSEVIER. 2021: AB44
  • Asthma as a predictor of more severe outcomes in COVID-19 infection Journal of Allergy and Clinical Immunology Eggert, L. E., Cao, S., He, Z., Sindher, S., Nadeau, K., Chinthrajah, R. 2021; 147 (2)
  • Asthma in Adults BMJ Best Practice Eggert, L., Majumdar, S. 2020
  • Acute Asthma Exacerbation in Adults BMJ Best Practice Majumdar, S., Eggert, L. 2020
  • Oncotype recurrence score (RS) and discordance in patients with secondary invasive breast events (SIBE). Zimmerman, B., Cascetta, K., Blanter, J., Eggert, L., Molot, M., Ru, M., Nayak, A., Bleiweiss, I., Jaffer, S., Tiersten, A. AMER SOC CLINICAL ONCOLOGY. 2019
  • Switching and Combining Biologics in Severe Asthma: Experience from a Large Academic Teaching Center Eggert, L., Chinthrajah, R. S. AMER THORACIC SOC. 2019
  • Retrospective analysis of oncotype DX recurrence score (RS) and discordance in patients with node-negative, ER+ breast cancer with recurrence Zimmerman, B. S., Cascetta, K. P., Ru, M., Eggert, L., Molot, M., Nayak, A., Bleiweiss, I., Tiersten, A. 2018

    View details for DOI 10.1158/1538-7445

  • One-Year Experience After Implementation of a Multidisciplinary Pulmonary Embolism Team ATS Eggert, L., Klipper, K., Kadian-Dodov, D., Reddy, R., DePalo, L., Lookstein, R., Poor, H. 2016

Latest information on COVID-19